Exelixis Inc (EXEL)
34.83
+0.18
(+0.52%)
USD |
NASDAQ |
Nov 21, 16:00
34.82
0.00 (0.00%)
After-Hours: 20:00
Exelixis Revenue (Quarterly): 539.54M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 539.54M |
| June 30, 2024 | 637.18M |
| March 31, 2024 | 425.23M |
| December 31, 2023 | 479.65M |
| September 30, 2023 | 471.92M |
| June 30, 2023 | 469.85M |
| March 31, 2023 | 408.79M |
| December 31, 2022 | 423.92M |
| September 30, 2022 | 411.74M |
| June 30, 2022 | 419.43M |
| March 31, 2022 | 355.98M |
| December 31, 2021 | 451.14M |
| September 30, 2021 | 328.42M |
| June 30, 2021 | 385.18M |
| March 31, 2021 | 270.23M |
| December 31, 2020 | 270.05M |
| September 30, 2020 | 231.09M |
| June 30, 2020 | 259.48M |
| March 31, 2020 | 226.92M |
| December 31, 2019 | 240.31M |
| September 30, 2019 | 271.70M |
| June 30, 2019 | 240.28M |
| March 31, 2019 | 215.49M |
| December 31, 2018 | 228.60M |
| September 30, 2018 | 225.40M |
| Date | Value |
|---|---|
| June 30, 2018 | 186.11M |
| March 31, 2018 | 213.72M |
| December 31, 2017 | 120.07M |
| September 30, 2017 | 152.51M |
| June 30, 2017 | 99.01M |
| March 31, 2017 | 80.89M |
| December 31, 2016 | 77.58M |
| September 30, 2016 | 62.19M |
| June 30, 2016 | 36.25M |
| March 31, 2016 | 15.43M |
| December 31, 2015 | 9.938M |
| September 30, 2015 | 9.854M |
| June 30, 2015 | 7.992M |
| March 31, 2015 | 9.388M |
| December 31, 2014 | 7.353M |
| September 30, 2014 | 6.291M |
| June 30, 2014 | 6.562M |
| March 31, 2014 | 4.905M |
| December 31, 2013 | 4.347M |
| September 30, 2013 | 5.466M |
| June 30, 2013 | 11.86M |
| March 31, 2013 | 9.669M |
| December 31, 2012 | 7.814M |
| September 30, 2012 | 13.31M |
| June 30, 2012 | 7.813M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
226.92M
Minimum
Mar 2020
637.18M
Maximum
Jun 2024
385.30M
Average
410.26M
Median
Revenue (Quarterly) Benchmarks
| Merck & Co Inc | 16.66B |
| ADMA Biologics Inc | 119.84M |
| Vericel Corp | 57.90M |
| Catalyst Pharmaceuticals Inc | 128.70M |
| Inovio Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 117.97M |
| Total Expenses (Quarterly) | 351.70M |
| EPS Diluted (Quarterly) | 0.40 |
| Enterprise Value | 8.758B |
| Gross Profit Margin (Quarterly) | 96.79% |
| Profit Margin (Quarterly) | 21.87% |
| Earnings Yield | 4.48% |
| Operating Earnings Yield | 5.80% |
| Normalized Earnings Yield | 5.105 |